Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants

Abstract

Background:Vascular endothelial growth factor is critically involved in ductus arteriosus closure. Polymorphisms in the vascular endothelial growth factor gene have been associated with several diseases in neonates and adults.Aim:Herein, we investigated if vascular endothelial growth factor polymorphism rs2010963 status is associated with patent ductus arteriosus incidence and/or pharmacological treatment success.Methods:We assessed rs2010963 status in 814 preterm infants (<1500 g birth weight) by means of restriction fragment length polymorphism analysis. DNA samples were obtained from dry-spot cards used for the German national newborn screening program. Clinical data were obtained by retrospective chart review.Results:We could not find any statistically significant difference in the incidence of patent ductus arteriosus depending on vascular endothelial growth factor rs2010963 polymorphism status. Furthermore, no statistically significant associations between vascular endothelial growth factor polymorphism rs2010963 status and cyclooxygenase inhibitor treatment success were observed.Conclusion:Our results indicate that there is no association between vascular endothelial growth factor polymorphism rs2010963 status and the occurrence of patent ductus arteriosus or the response to cyclooxygenase inhibitor treatment in a large cohort of preterm infants. Additional studies are needed to determine the role of genetic factors on patent ductus arteriosus incidence and treatment response.

Management of Patent Ductus Arteriosus in Premature Infants in 2020

“…Vascular endothelial growth factor (VEGF) has been thought to be involved in DA closure. However, VEGF polymorphism rs2010963 status has not been shown to affect PDA incidence or successful treatment with cyclooxygenase inhibitors in preterm infants (25).…”

“…The complications in the 241 infants weighing between 500 and 2,000 grams at the time of the TCPC at our institute included: coarctation of the aorta (2), pericardial effusion needing drainage (2), tricuspid valve injury (1), one procedure related mortality early in the experience, device embolization and retrieval (1) and left pulmonary artery stenosis requiring device retrieval (1). In contrast, the surgical group (n = 167) had two procedure related mortalities, wound dehiscence (2), residual PDA requiring re-intervention (4), Pneumothorax (3), Sepsis/pneumonia (4), left ventricular wall motion abnormality needing digoxin at discharge (1), worsening respiratory status (2), and post-ligation syndrome (25).…”

Genetic Polymorphisms of Vascular Endothelial Growth Factor in Neonatal Pathologies: A Systematic Search and Narrative Synthesis of the Literature

“…Thus, VEGF encourages the in growth of vasa vasorum and the recruitment of mononuclear cells to the intima of the ductus, which represents a crucial stage in the anatomical restructuring of the ductus arteriosus [ 68 , 69 ]. Based on this hypothesis, Sallmon et al [ 70 ] investigated whether the VEGF polymorphism rs2010963 status is associated with the incidence of patent arteriosus ductus and/or the efficiency of pharmacological treatment. The authors assessed the rs2010963 status in a cohort study that included 814 preterm infants with a weight less than 1500 g at birth using restriction fragment length polymorphism analysis.…”

“…The authors assessed the rs2010963 status in a cohort study that included 814 preterm infants with a weight less than 1500 g at birth using restriction fragment length polymorphism analysis. Their findings indicate that VEGF rs2010963 polymorphism status is not significantly associated with the rate of patent arteriosus ductus and is not correlated with the success of cyclooxygenase inhibitor treatment [ 70 ].…”